SmithKline cool on Novartis tie-up
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.SMITHKLINE BEECHAM yesterday played down suggestions that it is seeking a pounds 110bn merger with Novartis, the Swiss pharmaceutical group.
The company declined to comment on reports at the weekend that top executives from the two companies have met for "preliminary talks" but have yet to agree terms.
A SmithKline spokesman said: "We are a strong independent company. We don't need a merger."
The reports suggested that an outline discussion would value SmithKline at pounds 11.50 a share compared to the current share price of pounds 8.37. A special dividend payment to shareholders was also suggested.
One suggested rationale behind the deal was that it could prevent a counter-offer from Glaxo-Wellcome, the UK drugs group whose merger talks with SmithKline collapsed in acrimonious circumstances last year.
Glaxo is still thought to be keen on a deal with SmithKline, with industry experts suggesting that the retirement of Jan Leschly, SmithKline's chief executive next year, could trigger a fresh move by Glaxo's chairman, Sir Richard Sykes.
Novartis was formed in 1996 following the merger of two Swiss companies Sandoz and Ciba Geigy in a deal value at pounds 65bn.
Recent comments from Mr Leschly suggest he is happy with the way that SmithKline is trading and feels no pressing need for a major deal.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments